Total Payments
$192,842
2024 Payments
$3,922
Companies
41
Transactions
413
Medicare Patients
4,198
Medicare Billing
$827,345
Payment Breakdown by Category
Other$169,238 (87.8%)
Consulting$9,183 (4.8%)
Food & Beverage$8,710 (4.5%)
Travel$5,086 (2.6%)
Education$626.09 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $168,140 | 67 | 87.2% |
| Consulting Fee | $9,183 | 4 | 4.8% |
| Food and Beverage | $8,710 | 262 | 4.5% |
| Travel and Lodging | $5,086 | 52 | 2.6% |
| Long term medical supply or device loan | $1,098 | 12 | 0.6% |
| Education | $626.09 | 16 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $101,124 | 132 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $72,289 | 74 | $0 (2024) |
| Genentech USA, Inc. | $14,635 | 24 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $1,758 | 52 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $314.26 | 5 | $0 (2021) |
| Myriad Genetic Laboratories, Inc. | $237.62 | 2 | $0 (2023) |
| PFIZER INC. | $232.85 | 14 | $0 (2024) |
| Genmab U.S., Inc. | $229.17 | 2 | $0 (2024) |
| Amgen Inc. | $226.37 | 12 | $0 (2023) |
| Janssen Biotech, Inc. | $220.71 | 10 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,922 | 37 | AstraZeneca Pharmaceuticals LP ($2,381) |
| 2023 | $5,642 | 29 | Genentech USA, Inc. ($2,692) |
| 2022 | $28,188 | 29 | AstraZeneca Pharmaceuticals LP ($15,854) |
| 2021 | $20,825 | 22 | AstraZeneca Pharmaceuticals LP ($18,265) |
| 2020 | $12,997 | 17 | Merck Sharp & Dohme Corporation ($7,247) |
| 2019 | $50,692 | 124 | AstraZeneca Pharmaceuticals LP ($25,674) |
| 2018 | $40,875 | 116 | Merck Sharp & Dohme Corporation ($37,668) |
| 2017 | $29,701 | 39 | Merck Sharp & Dohme Corporation ($29,664) |
All Payment Transactions
413 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $24.43 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 12/10/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $8.84 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $22.07 | General |
| Category: Oncology | ||||||
| 11/21/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $15.47 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 10/23/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $30.34 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 10/16/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $19.18 | General |
| Category: Hematology/Oncology | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 09/19/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $16.07 | General |
| Category: Oncology | ||||||
| 09/18/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Oncology | ||||||
| 09/18/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $15.03 | General |
| Category: Oncology | ||||||
| 09/10/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 09/10/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: ONCOLOGY | ||||||
| 08/23/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 07/31/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: ONCOLOGY | ||||||
| 07/30/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: ONCOLOGY | ||||||
| 07/22/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: ONCOLOGY | ||||||
| 07/16/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: Oncology | ||||||
| 07/15/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 06/27/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $104.17 | General |
| Category: Oncology | ||||||
| 06/14/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $6.20 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 06/11/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $25.07 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 929 | 2,749 | $509,924 | $174,765 |
| 2022 | 8 | 1,259 | 2,754 | $508,968 | $210,346 |
| 2021 | 8 | 1,004 | 2,846 | $526,594 | $241,625 |
| 2020 | 8 | 1,006 | 2,806 | $528,123 | $200,610 |
Total Patients
4,198
Total Services
11,155
Medicare Billing
$827,345
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 291 | 1,558 | $316,274 | $109,852 | 34.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 436 | 855 | $119,700 | $37,992 | 31.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 78 | 78 | $30,654 | $10,498 | 34.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 59 | 173 | $24,047 | $10,428 | 43.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 31 | 31 | $9,610 | $2,816 | 29.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 15 | 33 | $6,699 | $2,225 | 33.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 19 | 21 | $2,940 | $954.74 | 32.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 252 | 1,005 | $204,015 | $91,719 | 45.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 170 | 495 | $100,485 | $37,872 | 37.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 401 | 653 | $91,420 | $37,425 | 40.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 222 | 259 | $36,260 | $13,422 | 37.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 74 | 201 | $27,939 | $11,130 | 39.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 48 | 48 | $18,864 | $7,612 | 40.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 29 | 29 | $11,397 | $4,181 | 36.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 23 | 23 | $7,130 | $2,434 | 34.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 12 | $4,668 | $1,864 | 39.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 15 | 15 | $3,990 | $1,570 | 39.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 14 | $2,800 | $1,116 | 39.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 334 | 1,652 | $335,356 | $157,654 | 47.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 432 | 820 | $114,800 | $52,313 | 45.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 93 | 223 | $30,997 | $12,241 | 39.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 71 | 71 | $27,903 | $12,199 | 43.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 27 | 27 | $8,370 | $3,511 | 42.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 20 | 20 | $4,000 | $1,641 | 41.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 14 | 14 | $3,724 | $1,516 | 40.7% |
About Dr. Maxwell Mcdonald, MD
Dr. Maxwell Mcdonald, MD is a Internal Medicine healthcare provider based in Shreveport, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/14/2005. The National Provider Identifier (NPI) number assigned to this provider is 1699764589.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Maxwell Mcdonald, MD has received a total of $192,842 in payments from pharmaceutical and medical device companies, with $3,922 received in 2024. These payments were reported across 413 transactions from 41 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($168,140).
As a Medicare-enrolled provider, Mcdonald has provided services to 4,198 Medicare beneficiaries, totaling 11,155 services with total Medicare billing of $827,345. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Shreveport, LA
- Active Since 10/14/2005
- Last Updated 07/09/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1699764589
Products in Payments
- KEYTRUDA (Biological) $101,075
- LYNPARZA (Drug) $69,296
- TECENTRIQ (Biological) $11,857
- Tecentriq (Biological) $2,685
- KISQALI (Drug) $1,219
- Tivdak (Drug) $229.17
- PROMACTA (Drug) $189.34
- VELCADE (Drug) $179.40
- PreciseTumor (Device) $154.31
- IMBRUVICA (Drug) $140.97
- IBRANCE (Drug) $133.90
- JEVTANA (Drug) $117.89
- EPKINLY (Drug) $109.93
- Enhertu (Drug) $106.22
- ERLEADA (Drug) $101.52
- JAKAFI (Drug) $97.79
- Neulasta (Biological) $91.98
- TASIGNA (Drug) $85.69
- PRECISETUMOR (Device) $83.31
- PLUVICTO (Drug) $79.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Shreveport
Dr. Sreedhara Alla, M.d, M.D
Internal Medicine — Payments: $637,707
Internal Medicine $637,707
Steven Bailey, Md, MD
Internal Medicine — Payments: $301,538
Internal Medicine $301,538
Prakash Peddi, Md, MD
Internal Medicine — Payments: $277,646
Internal Medicine $277,646
Laurie Grier, M.d, M.D
Internal Medicine — Payments: $69,555
Internal Medicine $69,555
Dr. Rajan Khanna, Md, MD
Internal Medicine — Payments: $66,411
Internal Medicine $66,411
Kenneth Abreo, Mbbs, MBBS
Internal Medicine — Payments: $44,563
Internal Medicine $44,563